Itolizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | CD6 |
Clinical data | |
Trade names | Alzumab |
Legal status | Approved in India |
Identifiers | |
CAS number | 1116433-11-4 |
ATC code | None |
UNII | XQQ2RHV14N |
Chemical data | |
Formula | ? |
(what is this?) (verify) | |
Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.[1] A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.[2] Biocon has received marketing authorization for the drug from the Drugs Controller General of India (DCGI).[3]
References
- ↑ http://www.biocon.com/docs/PR_080113.pdf?subLink=news
- ↑ http://www.thehindubusinessline.com/companies/article2789996.ece
- ↑ http://www.pharmabiz.com/NewsDetails.aspx?aid=73075&sid=2